by John Conrad | Jun 1, 2026 | iBIO News, Policy News
The passage of HB 4327 is a significant and long-overdue win for transparency, accountability, and — most importantly — for Illinois patients. For the first time, Illinois will have an independent, standardized accounting of how the 340B program actually operates in...
by John Conrad | May 27, 2026 | iBIO in the News, Policy News
Yesterday in Springfield, iBIO President and CEO John Conrad testified on legislation that would expand and reshape how Illinois interacts with the federal 340B drug discount program—underscoring a principle iBIO believes must come first: independent, enforceable...
